Please assess the completion status of the following clinical trial:

Trial Title: RotaTeq® and Meningococcus C Vaccine in Healthy Infants (V260-016)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy infants, aged from 6 weeks through full 7 weeks,~* Consent form signed by at least one parent or by the legal representative properly informed about the study,~* Parent(s) / legal representative able to understand the protocol requirements and to fill in the Diary Card.~Exclusion Criteria:~* History of congenital abdominal disorders, congenital malformation of the gastrointestinal tract that could predispose to intussusception, or abdominal surgery,~* Congenital fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency,~* Known or suspected impairment of immunological function,~* Known hypersensitivity to any component of RotaTeq® (e.g. sucrose) or of NeisVac-C® (including tetanus toxoid),~* Prior administration of any rotavirus vaccine,~* Prior administration of any vaccine within the 28 days prior to randomisation,~* Fever (rectal temperature ≥38.1°C) and/or acute diarrhoea and/or vomiting at randomisation,~* History of known prior rotavirus gastroenteritis, chronic diarrhoea, or failure to thrive,~* Any severe thrombocytopenia or any other coagulation disorder that would contraindicate intramuscular injection,~* Clinical evidence of active gastrointestinal illness,~* Receipt of intramuscular, oral, or intravenous corticosteroid treatment within the 14 days prior to randomisation. Note: Infants on inhaled and/or topical steroids may participate in the study,~* Infants residing in a household with an immunocompromised person,~* Prior receipt of a blood transfusion or blood products, including immunoglobulins.

- Gender: ALL
- Minimum Age: 42 Days
- Maximum Age: 55 Days
- Healthy Volunteers: t

Study Arms:
- Group 1: Concomitant Administration (Type: EXPERIMENTAL): Participants received 2 concomitant doses of RotaTeq® and MCC vaccine at 10-11 weeks of age and 20-21 weeks of age and a third dose of RotaTeq® at 24-25 weeks of age (and 28 to 42 days after the vaccine administration at 20-21 weeks of age).
- Group 2: Sequential Administration (Type: ACTIVE_COMPARATOR): Participants received 3 doses of RotaTeq® at 6-7 weeks of age, 15-16 weeks of age, and 24-25 weeks of age (and 28 to 42 days after the MMC vaccine administered at 20-21 weeks of age), and MCC vaccine at 10-11 weeks of age and 20-21 weeks of age.

Based on this trial design, predict the completion outcome and termination type (if applicable).